Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen

BACKGROUND: Although survival outcomes of multiple myeloma (MM) have improved with the development of new and effective agents, infection remains the major cause of morbidity and mortality. Here, we evaluated the efficacy of levofloxacin prophylaxis (in a real-world setting) during bortezomib, melph...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Su-In, Jung, Sung-Hoon, Yhim, Ho-Young, Jo, Jae-Cheol, Song, Ga-Young, Kim, Mihee, Ahn, Seo-Yeon, Ahn, Jae-Sook, Yang, Deok-Hwan, Kim, Hyeoung-Joon, Lee, Je-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958375/
https://www.ncbi.nlm.nih.gov/pubmed/35197371
http://dx.doi.org/10.5045/br.2021.2021176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958375/
https://www.ncbi.nlm.nih.gov/pubmed/35197371
http://dx.doi.org/10.5045/br.2021.2021176

Ejemplares similares